… Expert Perspectives Series – LCA10 and sepofarsen ProQR Expert Perspectives Series on Leber congenital amaurosis 10 and sepofarsen with Aniz Girach and Dr. Ian M. MacDonald. This …
… Full field stimulus testing (FST) to assess sepofarsen patient response in Leber congenital amaurosis … phase 1b/2 trial, 11 LCA10 patients received intravitreal sepofarsen . The goal was to evaluate patient response to …
… Results of a phase 1b/2 trial of intravitreal (IVT) sepofarsen (QR-110) antisense oligonucleotide in Leber … presents the 12-month results of a phase 1b/2 trial of sepofarsen. Following the results presentation, Dr. Russell …
… ARVO (2021) Russell SR et al., Safety and efficacy of sepofarsen in the second treated eye in a Ph1b/2 extension … Russell from Iowa University on the Safety and efficacy of sepofarsen in the second treated eye in a Ph1b/2 extension …
… Results of a phase 1b/2 trial of intravitreal (IVT) sepofarsen (QR-110) antisense oligonucleotide in Leber … Stephen Russel et al. Recognized with best poster award. Sepofarsen had a manageable safety profile and showed …
… Phase 2/3 Illuminate trial results of sepofarsen in CEP290-mediated LCA10 In top-line analyses, the … and secondary endpoints. No benefit was observed in either sepofarsen treatment arm versus the sham treated control arm. …
… ProQR update and additional sepofarsen Illuminate trial analyses ProQR has announced the … unmet need. We are also sharing additional analyses of the sepofarsen *Illuminate* trial. ProQR has announced the …
… Conference call additional sepofarsen analyses and company strategy update Webcast … additional analyses from the Phase 2/3 Illuminate trial of sepofarsen for LCA10 and provided an update on the company …
… ProQR Announces Publication in Nature Medicine for Sepofarsen in Leber Congenital Amaurosis 10 LEIDEN, … after a single treatment with antisense oligonucleotide sepofarsen: a case report ” describing durable vision …
